By Yoon Hang Kim, MD, MPH  |  Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Chronic illness patients — especially those navigating mold illness, Lyme disease, autoimmune conditions, or post-infectious syndromes — frequently encounter two acronyms that are both confusing and critically important: CIRS and MCAS. These conditions share a great deal of clinical overlap, yet they are mechanistically distinct, require different diagnostic approaches, and respond to different (though sometimes complementary) treatments.

In integrative medicine, we often describe CIRS as the "terrain" or "engine" driving systemic inflammation, while MCAS acts as the "amplifier" — layering additional hypersensitivity and reactivity on top of an already dysregulated immune system. Understanding both — and knowing when they coexist — is essential for patients who have "tried everything" without resolution.

What Is CIRS?

Chronic Inflammatory Response Syndrome (CIRS) is a multi-system, multi-symptom illness driven by persistent activation of the innate immune system following exposure to biotoxins. The most common trigger is water-damaged buildings (WDB), which harbor a complex mixture of mold species, actinomycetes, endotoxins, beta-glucans, and other immune-activating agents. Other upstream triggers include Lyme disease and its co-infections, certain marine toxins (e.g., ciguatera), and volatile organic compounds from mycotoxin-producing organisms.

CIRS, as developed and characterized by Dr. Ritchie Shoemaker, emphasizes a genetically susceptible host — particularly those with certain HLA-DR variants who cannot bind and excrete biotoxins through normal hepatobiliary pathways. Instead of clearing, toxins recirculate through enterohepatic pathways, sustaining chronic innate immune activation.

Key CIRS Features:

• Innate immune dysregulation — not classic autoimmunity
• Complement activation: elevated C4a is a hallmark marker
• Elevated inflammatory markers: MMP-9, TGF-β1, VEGF
• Neuroendocrine disruption: low MSH (melanocyte-stimulating hormone), abnormal ADH/osmolality
• HLA-DR susceptibility variants (approximately 25% of the general population)
• Failed Visual Contrast Sensitivity (VCS) test — a quick, inexpensive screening tool
• Multi-system symptom clusters: fatigue, brain fog, cognitive dysfunction, pain, sleep disturbance, GI complaints, mood changes

Important caveat: CIRS is not currently recognized as an established diagnosis by most academic medical centers, including major institutions. It is an active area of functional and integrative medicine research, with ongoing debate in the broader medical community about diagnostic criteria and biomarker specificity.

What Is MCAS?

Mast Cell Activation Syndrome (MCAS) is a disorder of mast cell dysregulation — a condition in which mast cells, the body's frontline immune sentinels, become hypersensitive and release excessive mediators in response to stimuli that would not ordinarily trigger such a reaction. These mediators include histamine, tryptase, prostaglandins (especially PGD2), leukotrienes, and heparin, among others.

Unlike classic mastocytosis (in which there is a clonal proliferation of mast cells), MCAS involves functionally overactive but not necessarily increased mast cells. The triggers are strikingly broad: foods (especially high-histamine foods), temperature changes, stress, physical exertion, infections, medications, fragrances, environmental toxins — and yes, mold and Lyme.

Key MCAS Features:

• Multi-system, episodic or chronic symptoms affecting at least two organ systems
• Classic symptoms: flushing, urticaria (hives), angioedema, itching, GI cramping, diarrhea, nausea, brain fog, palpitations
• Symptom improvement with mast-cell-targeted therapy (a diagnostic criterion)
• Laboratory support: elevated serum tryptase, elevated 24-hour urinary histamine or N-methylhistamine, elevated urinary PGD2 or 11-beta-PGF2α
• Note: Tryptase is often normal in MCAS — absence of elevation does not rule out the diagnosis

MCAS has growing recognition in mainstream allergy and immunology literature. The Consensus-2 criteria (Valent et al.) provide a framework that requires: (1) typical symptoms in at least two organ systems, (2) objective evidence of mast-cell mediator release, and (3) response to mast-cell-targeted therapy.

How CIRS and MCAS Overlap

The clinical overlap between CIRS and MCAS is substantial — and often frustrating for both patients and clinicians. Both conditions:

• Produce chronic, migratory, multi-system symptoms that shift over time
• Are triggered or worsened by water-damaged buildings, mold, and Lyme disease
• Manifest as what appears to be an overactive immune response without classic autoimmunity
• Frequently co-occur with histamine intolerance, multiple chemical sensitivity, and food reactivity
• Present a diagnostic challenge because standard workups often come back "normal"

In practice, many patients with mold-related illness or Lyme-related illness demonstrate features of both conditions simultaneously — which is why functional medicine clinicians often assess for both when evaluating complex chronic illness.

Key Differences at a Glance

The table below summarizes the most clinically relevant distinctions:

The Terrain-Amplifier Model: How CIRS Drives MCAS

One of the most useful clinical frameworks for patients who have both conditions is what integrative clinicians call the terrain-amplifier model:

CIRS establishes the terrain. Biotoxin-driven innate immune activation raises inflammatory signals — particularly C4a, complement fragments, and cytokines — that chronically stimulate tissue mast cells. The immune environment becomes one of persistent low-grade alarm.

MCAS amplifies the signal. Mast cells, already primed by the CIRS-driven innate immune milieu, respond excessively to routine triggers — histamine and other mediators are released in waves, producing vascular permeability, nerve sensitization, GI dysmotility, and skin reactions that layer on top of the CIRS symptom burden.

The practical implication: treating MCAS symptoms alone (with antihistamines and stabilizers) provides relief, but that relief is incomplete and often temporary if the CIRS driver is not addressed. Conversely, pursuing CIRS treatment (binders, remediation) without calming mast-cell reactivity can trigger massive MCAS flares as biotoxins mobilize.

This is why many experienced integrative clinicians stage treatment carefully — quieting the mast cells first, then introducing biotoxin binders gradually — rather than attacking both simultaneously at full force.

Diagnostic Approach in Practice

When to Suspect CIRS:

• Clear history of exposure to water-damaged buildings (workplace or home)
• Post-Lyme syndrome with persistent multi-system symptoms
• Positive or borderline VCS test (available at www.survivingmold.com)
• Symptom cluster consistent with Shoemaker criteria
• HLA-DR typing shows susceptible haplotype
• Elevated C4a, MMP-9, or TGF-β1 on laboratory panel
• Low MSH (≤35 pg/mL is suggestive)

When to Suspect MCAS:

• Episodic flushing, urticaria, angioedema, or anaphylactoid reactions
• Reactions to multiple foods, fragrances, medications, temperature, or stress
• GI symptoms that wax and wane without clear structural cause
• Symptom improvement (even partial) with antihistamines
• Elevated urinary N-methylhistamine, PGD2, or serum tryptase during flares
• History of allergic or atopic conditions (asthma, eczema, allergic rhinitis)

When to Assess for Both:

• History of mold or Lyme exposure plus episodic hypersensitivity reactions
• "Allergic to everything" phenotype with multi-system chronic illness
• Partial but incomplete response to MCAS treatment alone
• Persistent fatigue and cognitive symptoms that do not resolve with mast-cell stabilization

Treatment Overview

CIRS-Directed Treatment:

• Primary: Remove from biotoxin exposure — this is non-negotiable. Remediation or relocation.
• Binders: Cholestyramine (CSM) or colesevelam (Welchol) to interrupt enterohepatic recirculation of biotoxins — introduce slowly in MCAS-comorbid patients
• Treat MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) — nasal bacteria that perpetuate MSH suppression — with BEG nasal spray or similar protocols
• Sequential normalization of immune and neuroendocrine markers per Shoemaker protocol: C4a, MMP-9, VEGF, MSH, ADH/osmolality, and others
• VIP (vasoactive intestinal peptide) — used in late-stage CIRS protocol for persistent cases

MCAS-Directed Treatment:

• H1 antihistamines: cetirizine, loratadine, or fexofenadine (non-sedating preferred daytime); diphenhydramine or hydroxyzine for episodic or nighttime use
• H2 antihistamines: famotidine — blocks gastric and systemic histamine-2 receptors
• Mast-cell stabilizers: cromolyn sodium (oral liquid for GI involvement), ketotifen (not widely available in the US but effective)
• Leukotriene receptor antagonists: montelukast — targets prostaglandin and leukotriene pathways
• Low-Dose Naltrexone (LDN): 1.5–4.5 mg nightly — modulates toll-like receptor 4, reduces microglial and mast-cell activation; particularly relevant for patients with CIRS-MCAS overlap
• Quercetin: natural mast-cell stabilizer and anti-histamine — 500–1000 mg BID
• Vitamin C: natural antihistamine and antioxidant — 1000–2000 mg daily
• In severe or refractory MCAS: omalizumab (Xolair) — anti-IgE biologic with significant evidence for MCAS
• Trigger avoidance: low-histamine diet during flares, fragrance avoidance, temperature management, stress reduction

Note: In patients with CIRS-MCAS overlap, the order of treatment matters. Stabilizing mast-cell reactivity before introducing biotoxin binders reduces the risk of severe flaring during detoxification. This is a principle of clinical staging, not avoidance of treatment.

A Note on LDN in CIRS-MCAS Overlap

Low-Dose Naltrexone (LDN) deserves special mention in the context of CIRS-MCAS overlap. As a clinician with extensive LDN experience and as the founder of the LDN Support Group (9,000+ members), I have observed that LDN offers a unique position in the treatment cascade for these patients:

• It modulates TLR4 (toll-like receptor 4) signaling — relevant to both innate immune dysregulation in CIRS and mast-cell priming in MCAS
• It reduces microglial activation and neuroinflammation — addressing cognitive symptoms common to both conditions
• It has a favorable tolerability profile in most mold and Lyme patients when titrated carefully
• It does not directly block mast-cell mediators but appears to reduce the overall "volume" of innate immune signaling

Patients with CIRS-MCAS overlap often tolerate LDN well when started at very low doses (0.5 mg or even lower) and titrated slowly — consistent with the general approach of gentle titration in hypersensitive, mast-cell-activated patients.

Key Takeaways for Patients

• 1. CIRS and MCAS are different conditions with different mechanisms, but they frequently coexist in mold-exposed and Lyme-exposed patients.
• 2. Symptom overlap is significant — both produce fatigue, brain fog, GI dysfunction, and multi-system reactivity.
• 3. The terrain-amplifier model is the most clinically useful framework: CIRS drives chronic innate immune activation; MCAS amplifies it into episodic hypersensitivity.
• 4. You may need to treat both — sequentially or in parallel — for meaningful clinical improvement.
• 5. Start where the reactivity is highest. For most MCAS-dominant patients, stabilizing mast cells before addressing biotoxins produces safer, more tolerable outcomes.
• 6. Work with a clinician experienced in both frameworks. These are not conditions well-suited to isolated symptom management.

At Direct Integrative Care (www.directintegrativecare.com), I take a structured, evidence-informed approach to evaluating CIRS and MCAS — including full biotoxin panels, VCS testing, mast-cell mediator panels, and HLA-DR typing when indicated. For patients navigating the complexity of mold illness, Lyme disease, and chronic immune activation, precision matters. Reach out to learn whether a comprehensive CIRS-MCAS evaluation is right for you.

About Dr. Kim